EXACT Price To Sales Ratio vs Capex To Revenue Analysis

EXAS Stock

USD 55.14 2.23 4.21%

EXACT Sciences financial indicator trend analysis is much more than just examining EXACT Sciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether EXACT Sciences is a good investment. Please check the relationship between EXACT Sciences Price To Sales Ratio and its Capex To Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in EXACT Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy EXACT Stock please use our How to Invest in EXACT Sciences guide.

Price To Sales Ratio vs Capex To Revenue

Price To Sales Ratio vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of EXACT Sciences Price To Sales Ratio account and Capex To Revenue. At this time, the significance of the direction appears to have almost identical trend.

The correlation between EXACT Sciences' Price To Sales Ratio and Capex To Revenue is 0.97. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of EXACT Sciences, assuming nothing else is changed. The correlation between historical values of EXACT Sciences' Price To Sales Ratio and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of EXACT Sciences are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Price To Sales Ratio i.e., EXACT Sciences' Price To Sales Ratio and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

0.97

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing EXACT Sciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on EXACT Sciences sales, a figure that is much harder to manipulate than other EXACT Sciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from EXACT Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into EXACT Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in EXACT Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy EXACT Stock please use our How to Invest in EXACT Sciences guide.At this time, EXACT Sciences' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 2.5 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.54 in 2024.

	2021	2022	2023	2024 (projected)
Non Recurring	20.2M	16.0M	14.4M	13.7M
Reconciled Depreciation	180.3M	197.6M	206.6M	131.5M

Non Recurring Reconciled Depreciation

EXACT Sciences fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Net Debt	Cash	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Retained Earnings	Accounts Payable	Non Current Assets Total	Non Currrent Assets Other	Common Stock Total Equity	Other Current Assets	Property Plant And Equipment Gross	Common Stock	Intangible Assets	Property Plant Equipment	Good Will	Other Liab	Short Term Investments
Total Assets		0.99	0.9	0.64	0.9	0.65	0.89	0.99	0.99	0.79	0.95	0.97	0.99	-0.97	0.97	0.99	-0.34	0.9	0.99	0.96	0.88	0.98	0.99	0.99	0.91	0.29
Total Stockholder Equity	0.99		0.86	0.67	0.91	0.67	0.9	0.98	0.97	0.8	0.92	0.97	0.99	-0.94	0.94	0.97	-0.35	0.9	0.99	0.94	0.89	0.96	0.98	0.97	0.86	0.27
Net Debt	0.9	0.86		0.27	0.7	0.36	0.79	0.92	0.93	0.52	0.86	0.78	0.91	-0.92	0.95	0.94	-0.3	0.79	0.88	0.9	0.77	0.95	0.93	0.94	0.96	0.3
Cash	0.64	0.67	0.27		0.75	0.86	0.58	0.6	0.6	0.87	0.64	0.8	0.61	-0.58	0.52	0.54	-0.13	0.59	0.69	0.59	0.59	0.49	0.58	0.54	0.38	0.14
Other Assets	0.9	0.91	0.7	0.75		0.76	0.75	0.86	0.88	0.85	0.92	0.94	0.85	-0.81	0.8	0.86	-0.5	0.73	0.89	0.78	0.74	0.85	0.86	0.86	0.78	0.32
Cash And Short Term Investments	0.65	0.67	0.36	0.86	0.76		0.69	0.62	0.63	0.98	0.63	0.78	0.61	-0.61	0.58	0.52	-0.34	0.66	0.68	0.54	0.69	0.48	0.61	0.52	0.41	0.62
Common Stock Shares Outstanding	0.89	0.9	0.79	0.58	0.75	0.69		0.92	0.88	0.8	0.81	0.87	0.9	-0.92	0.89	0.86	-0.25	0.99	0.9	0.87	1.0	0.84	0.9	0.85	0.79	0.46
Other Stockholder Equity	0.99	0.98	0.92	0.6	0.86	0.62	0.92		0.99	0.76	0.94	0.95	0.99	-0.99	0.98	0.99	-0.29	0.93	0.99	0.97	0.91	0.98	0.99	0.99	0.93	0.28
Total Liab	0.99	0.97	0.93	0.6	0.88	0.63	0.88	0.99		0.77	0.96	0.96	0.98	-0.98	0.98	0.98	-0.33	0.88	0.99	0.96	0.86	0.97	0.99	0.98	0.94	0.31
Total Current Assets	0.79	0.8	0.52	0.87	0.85	0.98	0.8	0.76	0.77		0.76	0.89	0.76	-0.74	0.72	0.68	-0.34	0.77	0.81	0.7	0.79	0.65	0.75	0.68	0.57	0.57
Other Current Liab	0.95	0.92	0.86	0.64	0.92	0.63	0.81	0.94	0.96	0.76		0.94	0.9	-0.94	0.93	0.94	-0.39	0.81	0.95	0.89	0.79	0.93	0.92	0.94	0.94	0.26
Total Current Liabilities	0.97	0.97	0.78	0.8	0.94	0.78	0.87	0.95	0.96	0.89	0.94		0.95	-0.92	0.91	0.93	-0.32	0.87	0.98	0.92	0.86	0.9	0.95	0.93	0.83	0.3
Property Plant And Equipment Net	0.99	0.99	0.91	0.61	0.85	0.61	0.9	0.99	0.98	0.76	0.9	0.95		-0.96	0.96	0.98	-0.29	0.9	0.99	0.97	0.89	0.97	0.99	0.98	0.89	0.28
Retained Earnings	-0.97	-0.94	-0.92	-0.58	-0.81	-0.61	-0.92	-0.99	-0.98	-0.74	-0.94	-0.92	-0.96		-0.98	-0.96	0.26	-0.92	-0.97	-0.96	-0.9	-0.94	-0.96	-0.96	-0.93	-0.29
Accounts Payable	0.97	0.94	0.95	0.52	0.8	0.58	0.89	0.98	0.98	0.72	0.93	0.91	0.96	-0.98		0.97	-0.26	0.89	0.97	0.96	0.87	0.96	0.98	0.96	0.95	0.34
Non Current Assets Total	0.99	0.97	0.94	0.54	0.86	0.52	0.86	0.99	0.98	0.68	0.94	0.93	0.98	-0.96	0.97		-0.32	0.87	0.97	0.96	0.85	1.0	0.99	1.0	0.94	0.2
Non Currrent Assets Other	-0.34	-0.35	-0.3	-0.13	-0.5	-0.34	-0.25	-0.29	-0.33	-0.34	-0.39	-0.32	-0.29	0.26	-0.26	-0.32		-0.16	-0.27	-0.07	-0.25	-0.35	-0.27	-0.32	-0.28	-0.44
Common Stock Total Equity	0.9	0.9	0.79	0.59	0.73	0.66	0.99	0.93	0.88	0.77	0.81	0.87	0.9	-0.92	0.89	0.87	-0.16		0.91	0.9	0.99	0.85	0.91	0.86	0.79	0.38
Other Current Assets	0.99	0.99	0.88	0.69	0.89	0.68	0.9	0.99	0.99	0.81	0.95	0.98	0.99	-0.97	0.97	0.97	-0.27	0.91		0.97	0.89	0.96	0.99	0.97	0.9	0.27
Property Plant And Equipment Gross	0.96	0.94	0.9	0.59	0.78	0.54	0.87	0.97	0.96	0.7	0.89	0.92	0.97	-0.96	0.96	0.96	-0.07	0.9	0.97		0.85	0.94	0.97	0.96	0.9	0.17
Common Stock	0.88	0.89	0.77	0.59	0.74	0.69	1.0	0.91	0.86	0.79	0.79	0.86	0.89	-0.9	0.87	0.85	-0.25	0.99	0.89	0.85		0.83	0.89	0.84	0.75	0.44
Intangible Assets	0.98	0.96	0.95	0.49	0.85	0.48	0.84	0.98	0.97	0.65	0.93	0.9	0.97	-0.94	0.96	1.0	-0.35	0.85	0.96	0.94	0.83		0.98	1.0	0.94	0.2
Property Plant Equipment	0.99	0.98	0.93	0.58	0.86	0.61	0.9	0.99	0.99	0.75	0.92	0.95	0.99	-0.96	0.98	0.99	-0.27	0.91	0.99	0.97	0.89	0.98		0.98	0.92	0.31
Good Will	0.99	0.97	0.94	0.54	0.86	0.52	0.85	0.99	0.98	0.68	0.94	0.93	0.98	-0.96	0.96	1.0	-0.32	0.86	0.97	0.96	0.84	1.0	0.98		0.95	0.18
Other Liab	0.91	0.86	0.96	0.38	0.78	0.41	0.79	0.93	0.94	0.57	0.94	0.83	0.89	-0.93	0.95	0.94	-0.28	0.79	0.9	0.9	0.75	0.94	0.92	0.95		0.23
Short Term Investments	0.29	0.27	0.3	0.14	0.32	0.62	0.46	0.28	0.31	0.57	0.26	0.3	0.28	-0.29	0.34	0.2	-0.44	0.38	0.27	0.17	0.44	0.2	0.31	0.18	0.23

Click cells to compare fundamentals

EXACT Sciences Account Relationship Matchups

EXACT Sciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.5B	4.9B	6.7B	6.2B	6.5B	6.8B
Total Stockholder Equity	2.3B	2.8B	3.4B	3.0B	3.1B	3.3B
Net Debt	769.0M	(27.1M)	2.0B	2.2B	1.9B	2.0B
Cash	177.3M	1.5B	315.5M	242.5M	605.4M	635.6M
Other Assets	20.3M	63.8M	74.6M	36.7M	42.2M	44.3M
Cash And Short Term Investments	323.7M	1.8B	1.0B	632.1M	777.6M	816.5M
Common Stock Shares Outstanding	131.3M	151.1M	171.3M	176.4M	180.1M	189.2M
Liabilities And Stockholders Equity	3.5B	4.9B	6.7B	6.2B	6.5B	6.8B
Other Stockholder Equity	3.4B	4.3B	6.0B	6.3B	6.6B	6.9B
Total Liab	1.2B	2.1B	3.3B	3.2B	3.3B	3.5B
Total Current Assets	557.0M	2.2B	1.4B	982.3M	1.2B	1.3B
Other Current Liab	8.5M	267.2M	423.3M	306.3M	352.1M	369.7M
Total Current Liabilities	236.5M	575.8M	517.1M	412.7M	514.7M	540.4M
Property Plant And Equipment Net	581.8M	576.6M	754.5M	851.8M	842.1M	884.2M
Retained Earnings	(1.1B)	(2.0B)	(2.6B)	(3.3B)	(3.5B)	(3.3B)
Accounts Payable	26.0M	35.7M	67.8M	74.9M	78.8M	82.8M
Non Current Assets Total	2.9B	2.7B	5.3B	5.2B	5.3B	5.5B
Non Currrent Assets Other	20.3M	(193.1M)	(451.3M)	(425.5M)	177.4M	186.3M
Common Stock Total Equity	1.5M	1.6M	1.7M	1.8M	2.0M	2.1M
Other Current Assets	40.9M	66.3M	74.1M	73.9M	85.6M	89.9M
Property Plant And Equipment Gross	581.8M	576.6M	754.5M	851.8M	1.3B	1.3B
Accumulated Other Comprehensive Income	(100K)	526K	(1.4M)	(5.2M)	1.4M	1.5M
Common Stock	1.5M	1.6M	1.7M	1.8M	1.8M	1.9M
Intangible Assets	1.1B	848.4M	2.1B	2.0B	1.9B	2.0B
Property Plant Equipment	455.3M	450.7M	754.5M	684.8M	787.5M	826.8M
Good Will	1.2B	1.2B	2.3B	2.3B	2.4B	2.5B
Other Liab	28.1M	61.6M	417.8M	345.1M	396.8M	416.7M
Short Term Investments	146.4M	348.7M	715.0M	389.6M	172.3M	222.6M
Non Current Liabilities Total	981.2M	1.5B	2.8B	2.8B	2.8B	3.0B
Current Deferred Revenue	193.3M	233.6M	398.6M	3.1M	76.9M	84.2M
Short Long Term Debt Total	946.3M	1.5B	2.4B	2.4B	2.6B	2.7B
Long Term Debt	827.6M	1.3B	2.2B	2.2B	2.3B	2.4B
Net Tangible Assets	(58.7M)	737.4M	(1.0B)	697.1M	627.4M	658.8M
Retained Earnings Total Equity	(1.1B)	(2.0B)	(2.6B)	(3.3B)	(2.9B)	(2.8B)
Long Term Debt Total	4.3M	688.8M	827.6M	2.2B	2.5B	2.6B
Capital Surpluse	3.4B	4.8B	6.0B	6.3B	7.3B	7.6B
Inventory	61.7M	92.3M	105.0M	118.3M	127.5M	133.8M
Non Current Liabilities Other	34.9M	61.6M	417.8M	352.5M	336.0M	352.8M
Short Term Debt	8.7M	330.2M	25.9M	31.6M	83.8M	44.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for EXACT Stock Analysis

When running EXACT Sciences' price analysis, check to measure EXACT Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EXACT Sciences is operating at the current time. Most of EXACT Sciences' value examination focuses on studying past and present price action to predict the probability of EXACT Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EXACT Sciences' price. Additionally, you may evaluate how the addition of EXACT Sciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC